Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company’s phase I clinical trial for Parkinson’s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells’ (iPSCs) play in the trial, and they also discuss the company’s investigational cell therapy, bemdaneprocel.
Related News
Press Releases
BlueRock Therapeutics announces publication in Nature of 18-month data from Phase 1 clinical trial for bemdaneprocel, an investigational cell therapy for Parkinson’s disease
April 16, 2025
Press Releases
